|Table of Contents|

Research progress on determination,follow-up and treatment of biochemical recurrence of epithelial ovarian cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 14
Page:
2714-2719
Research Field:
Publishing date:

Info

Title:
Research progress on determination,follow-up and treatment of biochemical recurrence of epithelial ovarian cancer
Author(s):
LIAO Huiyan1; XIAO Jing2
1.The Second Clinical College of Guangzhou University of Chinese Medicine,Guangdong Guangzhou 510410,China;2.The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangdong Guangzhou 510120,China.
Keywords:
epithelial ovarian cancer; biological recurrence; CA125
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.14.028
Abstract:
During the follow-up of patients with epithelial ovarian cancer(EOC) after standard initial treatment,many patients will experience a period that their serum level of tumor markers increase significantly but they have not any symptoms of recurrence in terms of both physical examination and imaging examination.Accordingly,some clinicians have believed that the diagnosis of recurrence can be predicted by the tumor markers which is in excess of a certain level and this stage is called "biochemical relapse".However,tumor markers are various and the threshold of them are so unclear that the concept of "biochemical relapse" has not been widely accepted therefore.This situation in a way has a negative impact on the decisions of both follow-up and therapies when dealing with patients in this state in clinical practice and it also confuses researchers when they plan the research schemes.The purpose of this review is mainly to discuss the related problems in the "biochemical relapse" state,such as tumor marker threshold,frequency of test and methods to rule out clinical relapse,in order to give clinicians a clearer insight into EOC disease.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］SALANI R,BACKES FJ,FUNG MF,et al.Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies:Society of Gynecologic Oncologists recommendations［J］.Am J Obstet Gynecol,2011,204(6):466-478.
［3］RUSTIN GJ,VAN DER BURG ME,GRIFFIN CL,et al.Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955):a randomised trial［J］.Lancet,2010,376(9747):1155-1163.
［4］SMITS M,MEHRA N,SEDELAAR M,et al.Molecular biomarkers to guide precision medicine in localized prostate cancer［J］.Expert Rev Mol Diagn,2017,17(8):791-804.
［5］KRISTELEIT R,DAVIDENKO I,SHIRINKIN V,et al.A randomised,open-label,phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer,primary peritoneal carcinoma,or fallopian tube cancer［J］.Gynecol Oncol,2017,146(3):484-490.
［6］PIGNATA S,CANNELLA L,LEOPARDO D,et al.Follow-up with CA125 after primary therapy of advanced ovarian cancer:in favor of continuing to prescribe CA125 during follow-up［J］.Ann Oncol,2011,22(Suppl 8):viii40-viii44.
［7］WANG Z,HUANG Y,LONG L,et al.Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression［J］.J Ovarian Res,2021,14(1):91.
［8］JELOVAC D,ARMSTRONG DK.Recent progress in the diagnosis and treatment of ovarian cancer［J］.CA Cancer J Clin,2011,61(3):183-203.
［9］PECORELLI S,FAVALLI G,GADDUCCI A,et al.Phase Ⅲ trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy:final results of the after-6 protocol 1［J］.J Clin Oncol,2009,27(28):4642-4648.
［10］DU BOIS A,KRISTENSEN G,RAY-COQUARD I,et al.Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer(AGO-OVAR 12):a randomised,double-blind,placebo-controlled phase 3 trial［J］.Lancet Oncol,2016,17(1):78-89.
［11］LEDERMANN JA,HACKSHAW A,KAYE S,et al.Randomized phase Ⅱ placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer［J］.J Clin Oncol,2011,29(28):3798-3804.
［12］LHEUREUX S,GOURLEY C,VERGOTE I,et al.Epithelial ovarian cancer［J］.Lancet,2019,393(10177):1240-1253.
［13］BEREK JS,TAYLOR PT,GORDON A,et al.Randomized,placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer［J］.J Clin Oncol,2004,22(17):3507-3516.
［14］KARAM AK，KARLAN BY.Ovarian cancer:the duplicity of CA125 measurement［J］.Nat Rev Clin Oncol,2010,7(6):335-339.
［15］JACOBS IJ,BAST RC.The CA125 tumour-associated antigen:a review of the literature［J］.Hum Reprod,1989,4(1):1-12.
［16］RUSTIN GJ,NELSTROP AE,TUXEN MK,et al.Defining progression of ovarian carcinoma during follow-up according to CA125:a North Thames Ovary Group study［J］.Ann Oncol,1996,7(4):361-364.
［17］RUSTIN GJ,MARPLES M,NELSTROP AE,et al.Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels［J］.J Clin Oncol,2001,19(20):4054-4057.
［18］VERGOTE I,RUSTIN GJ,EISENHAUER EA,et al.Re:new guidelines to evaluate the response to treatment in solid tumors(ovarian cancer).Gynecologic Cancer Inter Group［J］.J Natl Cancer Inst,2000,92(18):1534-1545.
［19］RUSTIN GJ,VERGOTE I,EISENHAUER E,et al.Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Inter Group(GCIG)［J］.Int J Gynecol Cancer,2011,21(2):419-423.
［20］EISENHAUER EA,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)［J］.Eur J Cancer,2009,45(2):228-247.
［21］LEVY T,WEISER R,BOAZ M,et al.Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian,primary peritoneal,and tubal cancers,who,after initial treatment,had a complete clinical response［J］.Int J Gynecol Cancer,2012,22(8):1344-1348.
［22］GIULIANI M,GUI B,VALENTINI AL,et al.Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery.Correlation between CT findings and CA 125 levels［J］.Minerva Ginecol,2017,69(6):538-547.
［23］WANG F,YE Y,XU X,et al.CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery［J］.J Ovarian Res,2013,6(1):14.
［24］SHINAGARE AB,BALTHAZAR P,IP IK,et al.High-grade serous ovarian cancer:Use of machine learning to predict abdominopelvic recurrence on CT on the basis of serial cancer antigen 125 levels［J］.J Am Coll Radiol,2018,15(8):1133-1138.
［25］LEVY T,WEISER R,BOAZ M,et al.The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian,primary peritoneal and tubal carcinoma patients［J］.Gynecol Oncol,2013,129(1):165-168.
［26］GUO N,PENG Z.Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study［J］.J Ovarian Res,2017,10(1):14.
［27］GADDUCCI A,NOTARNICOLA M,MENICHETTI A,et al.Has serum CA125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum-and paclitaxel-based chemotherapy［J］.Eur J Gynaecol Oncol,2016,37(2):182-188.
［28］NCCN Clinical Practice Guideline in Oncology.Ovarian cancer including fallopian tube cancer and primary peritoneal cancer［EB/OL］.［2022-9-16］.https://www.nccn.org/ guidelines/guidelines-detail?category=1&id=1453
［29］SOLETORMOS G,DUFFY MJ,OTHMAN ABU HASSAN S,et al.Clinical use of cancer biomarkers in epithelial ovarian cancer:Updated Guidelines From the European Group on tumor markers［J］.Int J Gynecol Cancer,2016,26(1):43-51.
［30］RUSTIN GJ,TIMMERS P,NELSTROP A,et al.Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide［J］.J Clin Oncol,2006,24(1):45-51.
［31］RUSTIN GJ,VAN DER BURG M,GRIFFIN C,et al.Early versus delayed treatment of relapsed ovarian cancer［J］.Lancet,2011,377(9763):380-381.
［32］RAY-COQUARD I,PAUTIER P,PIGNATA S,et al.Olaparib plus bevacizumab as first-line maintenance in ovarian cancer［J］.N Engl J Med,2019,381(25):2416-2428.
［33］FISCHEROVA D,BURGETOVA A.Imaging techniques for the evaluation of ovarian cancer［J］.Best Pract Res Clin Obstet Gynaecol,2014,28(5):697-720.
［34］PAIK ES,KIM TJ,LEE YY,et al.Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer［J］.J Gynecol Oncol,2016,27(5):e46.
［35］LAIFER-NARIN SL,GENESTINE WF,OKECHUKWU NC,et al.The role of computed tomography and magnetic resonance imaging in gynecologic oncology［J］.PET Clin,2018,13(2):127-141.
［36］CHEN YM,CHEN T,ZEE CS,et al.Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center［J］.Nucl Med Commun,2014,35(4):347-352.
［37］ANTUNOVIC L,CIMITAN M,BORSATTI E,et al.Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas:correlation with histology,serum CA-125 assay,and conventional radiological modalities［J］.Clin Nucl Med,2012,37(8):e184-188.
［38］TAKEKUMA M,MAEDA M,OZAWA T,et al.Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer［J］.Int J Clin Oncol,2005,10(3):177-181.
［39］GADDUCCI A,SIMONETTI E,MANCA G,et al.Positron emission tomography/computed tomography in platinum-sensitive pecurrent ovarian cancer:A single-center Italian study［J］.Anticancer Res,2020,40(4):2191-2197.
［40］VIRARKAR M,GANESHAN D,GULATI AT,PALMQUIST S,et al.Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review［J］.Abdom Radiol(NY),2021,46(6):2323-2349.
［41］RUSTIN G.Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed［J］.Ann Oncol,2011,22(Suppl_8):viii45-viii48.
［42］PENSON RT,VALENCIA RV,CIBULA D,et al.Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation(SOLO3):A randomized phase Ⅲ trial［J］.J Clin Oncol,2020,38(11):1164-1174.
［43］VETTER MH,HAYS JL.Use of targeted therapeutics in epithelial ovarian cancer:A review of current literature and future directions［J］.Clin Ther,2018,40(3):361-371.
［44］ABRAMS D,MCCULLOCH M,COHEN M,et al.A survey of licensed acupuncturists in the San Francisco Bay area:Prevalence of treating oncology patients［J］.Integr Cancer Ther,2018,17(1):92-98.
［45］CRAMER DW,FICHOROVA RN,TERRY KL,et al.Anti-CA15.3 and anti-CA125 antibodies and ovarian cancer risk:Results from the EPIC cohort［J］.Cancer Epidemiol Biomarkers Prev,2018,27(7):790-804.
［46］COLOMBO N,SESSA C,DU BOIS A,et al.ESMO-ESGO consensus conference recommendations on ovarian cancer:pathology and molecular biology,early and advanced stages,borderline tumours and recurrent diseasedagger［J］.Ann Oncol,2019,30(5):672-705.
［47］NICHOLSON BD,LEE MM,WIJERATNE D,et al.Trends in cancer antigen 125 testing 2003-2014:A primary care population-based cohort study using laboratory data［J］.Eur J Cancer Care(Engl),2019,28(1):e12914.
［48］AZAD NS,ANNUNZIATA CM,STEINBERG SM,et al.Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy［J］.Cancer,2008,112(8):1726-1732.
［49］CAPRIGLIONE S,LUVERO D,PLOTTI F,et al.Ovarian cancer recurrence and early detection:may HE4 play a key role in this open challenge?A systematic review of literature［J］.Medical Oncology(Northwood,London,England),2017,34(9):164.
［50］DOCHEZ V,CAILLON H,VAUCEL E,et al.Biomarkers and algorithms for diagnosis of ovarian cancer:CA125,HE4,RMI and ROMA,a review［J］.Journal of Ovarian Research,2019,12(1):28.
［51］LIANG L,JIANG Y,CHEN J,et al.B7-H4 expression in ovarian serous carcinoma:a study of 306 cases［J］.Human Pathology,2016,57:1-6.
［52］ZHANG Y,CAO L,FU Z,et al.Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer［J］.Journal of Cancer Research and Therapeutics,2015,11(2):375-380.
［53］GUO J,YANG W,PAK D,et al.Osteopontin,macrophage migration inhibitory factor and anti-interleukin-8 autoantibodies complement CA125 for detection of early stage ovarian cancer［J］.Cancers,2019,11(5):596 .

Memo

Memo:
广东省中医院俞云学术经验传承工作室建设项目（编号：E43728）；2022年广东省中医药局中医药科研项目（编号：20221174）
Last Update: 1900-01-01